Donepezil Sustained-Release Formulation Using Gel-Forming Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of donepezil for Alzheimer's disease cause sharp spikes in blood plasma levels, leading to undesirable side effects such as anxiety, nightmares, and gastrointestinal issues due to immediate release, whereas sustained-release formulations aim to maintain therapeutic levels with reduced frequency and side effects.
Innovation Solution
A sustained-release formulation comprising an acetylcholinesterase inhibitor like donepezil combined with at least two gel-forming polymers, such as Carbopol and HPMC, which form a viscous gel layer upon contact with gastrointestinal fluids, controlling the release rate and maintaining therapeutic levels over a longer period.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If immediate release formulation is used, then rapid onset of action is achieved, but sharp spikes in blood plasma levels cause undesirable side effects
Solution Approach 1:
The patent changes the release rate parameter of donepezil by incorporating it into a matrix containing multiple gel-forming polymers (carbomer, hydroxypropyl cellulose, hydroxypropyl methyl cellulose) at specific concentrations. This matrix controls the dissolution and release kinetics, transforming the immediate release profile into a sustained release profile that maintains plasma concentrations within the therapeutic window without sharp spikes, thereby reducing side effects while preserving therapeutic efficacy.
Solution Approach 2:
The patent uses a composite matrix formulation combining multiple gel-forming polymers (carbomer, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose) with donepezil. This composite material provides synergistic gel formation and viscosity control, creating a sustained release system that modulates drug release kinetics and prevents plasma concentration spikes while maintaining therapeutic levels.
2Ease of operation
If immediate release formulation is used, then simple administration is maintained, but frequent dosing is required to maintain therapeutic levels
Solution Approach 1:
The patent modifies the release rate parameter of donepezil through a multi-polymer matrix system, extending the duration of therapeutic action from several hours (immediate release) to approximately 24 hours or longer (sustained release). This allows once-daily or less frequent dosing while maintaining therapeutic plasma concentrations, reducing the time loss associated with frequent dosing without complicating the administration regimen.
Solution Approach 2:
The sustained release matrix ensures continuous release of donepezil over an extended period, maintaining therapeutic plasma concentrations continuously rather than allowing peaks and troughs. This continuous action provides consistent therapeutic effect throughout the dosing interval, eliminating the need for frequent redosing while preserving ease of administration.
3Object-affected harmful factors
If sustained release formulation is used, then peak plasma concentrations are reduced, but drug release rate control complexity increases
Solution Approach 1:
The patent employs a composite formulation of multiple gel-forming polymers (carbomer, hydroxypropyl cellulose, hydroxypropyl methyl cellulose) that work synergistically to control drug release. The combination of these polymers creates a complex gel matrix structure that provides effective sustained release and peak concentration control, but the formulation complexity is managed through standardized manufacturing processes and well-characterized polymer interactions.
Solution Approach 2:
The patent optimizes the concentrations of each polymer component (carbomer at 2-10%, hydroxypropyl cellulose at 5-20%, hydroxypropyl methyl cellulose at 5-20%) to achieve the desired release profile. By carefully controlling these compositional parameters, the formulation achieves effective peak concentration reduction while keeping the manufacturing process relatively straightforward through wet granulation and compression techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of gel-forming polymers in the formulation slows and smoothes the release of donepezil, reducing peak plasma concentrations and minimizing adverse side effects while maintaining therapeutic efficacy, thus improving patient compliance and reducing side effects.
Implementation Method 1
at least two gel-forming polymers, such as Carbopol and HPMC, which form a viscous gel layer upon contact with gastrointestinal fluids
Implementation Method 2
form a viscous gel layer upon contact with gastrointestinal fluids, controlling the release rate
Implementation Method 3
The combination of gel-forming polymers in the formulation slows and smoothes the release of donepezil, reducing peak plasma concentrations
Data Source
AI summary
A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.